A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Sponsor: Merus B.V.
Listed as NCT03526835, this PHASE1/PHASE2 trial focuses on Advanced/Metastatic Solid Tumors and Colorectal Cancer and remains actively recruiting participants. Sponsored by Merus B.V., it has been updated 13 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 8 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Unknown Status → Recruiting · Phase: PHASE1 → PHASE1_PHASE2
-
Feb 2021 — Mar 2023 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Sep 2018 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merus B.V.
For direct contact, visit the study record on ClinicalTrials.gov .